• 1
    Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013 Jul 2. doi: 10.1038/nrgastro.2013.107.
  • 2
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.e1.
  • 3
    Mishra A, Otgonsuren M, Venkatesan C, Afendy M, Erario M, Younossi ZM. The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int 2013;33:1281-1286.
  • 4
    Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther 2013;38:1065-1075.
  • 5
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
  • 6
    Les I, Doval E, Flavià M, Jacas C, Cárdenas G, Esteban R, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010;22:221-227.
  • 7
    Loria A, Escheik C, Gerber NL, Younossi ZM. Quality of life in cirrhosis. Curr Gastroenterol Rep 2013;15:301.
  • 8
    Häuser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2004;2:157-163.
  • 9
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
  • 10
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-816.
  • 11
    Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004;40:675-681.
  • 12
    Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2013 Nov 19. doi: 10.1016/j.jhep.2013.11.009.
  • 13
    Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013 Dec 5. doi: 10.1016/j.cgh.2013.11.032.
  • 14
    Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CHC). J Hepatol 2013 Dec 10. doi: 10.1016/j.jhep.2013.12.006.
  • 15
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al.; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
  • 16
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
  • 17
    Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 and 3: The VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013), Washington, DC, November 1-5, 2013. Abstract 1085.
  • 18
    Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-413; discussion, 415-420.
  • 19
    Younossi Z, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
  • 20
    Webster K, Odom L, Peterman A, Lent L, Cella D. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999;8:604.
  • 21
    Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-365.
  • 22
    Stewart B, Mikocka-Walus A, Morgan J, Colman A, Phelps M, Harley H, Andrews J. Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors. Australas Psychiatry 2012;20:496-500.
  • 23
    Sarkar S, Schaefer M. Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics 2013 Sep 4. pii: S0033-3182(13)00130-8. doi: 10.1016/j.psym.2013.06.015. [Epub ahead of print].
  • 24
    John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009;104:2439-2448.
  • 25
    Manns MP, Cornberg M. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 2013;13:378-379.
  • 26
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-816.
  • 27
    Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890. J Hepatol 2013;59:434-441.